Simplify Logo

Full-Time

Senior Director

Commercial Regulatory Affairs

Posted on 6/27/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Bachelor’s degree in science or equivalent experience.
  • 13+ years’ experience in promotional regulatory affairs (drugs).
  • Strong knowledge of FDA promotional regulations, guidance, best practices, and their evolution.
  • Strong, current understanding of 'scientific exchange' and pre-approval discussions; ability to unpack and deploy these concepts in practice.
  • Confident in interactions with commercial and medical affairs leaders.
  • Collaborative and solution-oriented mindset and approach.
  • Strong verbal and written communication and influencing skills.
Responsibilities
  • Establish the commercial regulatory function at Revolution Medicines.
  • Lead and participate on cross-functional teams to assess and mitigate regulatory and compliance risks related to commercialization of drug products.
  • Collaborate on or lead new processes and review systems to support commercialization (e.g., Standard Operating Procedures, Veeva PromoMats, Veeva MedComms).
  • Collaborate with relevant commercial and medical stakeholders to ensure business objectives are achieved in a compliant manner.
  • Train the company at all levels on regulatory expectations and requirements at different phases of the product lifecycle, including pre-approval discussions.
  • Serve as an assigned contact and maintain a positive relationship with the US FDA Office of Prescription Drug Promotion (OPDP).
  • Provide promotional regulatory strategy and prepare submission of materials at the time of dissemination (Form FDA 2253) or for advisory comment requests.
  • Ensure the company is launch-ready and regulatory is appropriately resourced to ensure success.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

44%

2 year growth

131%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE